Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractThe coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is a global health emergency. An attractive drug target among coronaviruses is the main protease (Mpro, also called 3CLpro) because of its essential role in processing the polyproteins that are translated from the viral RNA. We report the x-ray structures of the unliganded SARS-CoV-2 Mpro and its complex with an α-ketoamide inhibitor. This was derived from a previously designed inhibitor but with the P3-P2 amide bond incorporated into a pyridone ring to enhance the half-life of the compound in plasma. On the basis of the unliganded structure, we developed the lead compound into a potent inhibitor of the SARS-CoV-2 Mpro The pharmacokinetic characterization of the optimized inhibitor reveals a pronounced lung tropism and suitability for administration by the inhalative route.
CitationScience. 2020;368(6489):409‐412. doi:10.1126/science.abb3405
AffiliationHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.
JournalScience (New York, N.Y.)
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
- Authors: Goyal B, Goyal D
- Issue date: 2020 Jun 8
- Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M<sup>pro</sup> enzyme through in silico approach.
- Authors: Gurung AB, Ali MA, Lee J, Farah MA, Al-Anazi KM
- Issue date: 2020 Aug 15
- Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.
- Authors: Hung HC, Ke YY, Huang SY, Huang PN, Kung YA, Chang TY, Yen KJ, Peng TT, Chang SE, Huang CT, Tsai YR, Wu SH, Lee SJ, Lin JH, Liu BS, Sung WC, Shih SR, Chen CT, Hsu JT
- Issue date: 2020 Aug 20
- Optimization Rules for SARS-CoV-2 M<sup>pro</sup> Antivirals: Ensemble Docking and Exploration of the Coronavirus Protease Active Site.
- Authors: Stoddard SV, Stoddard SD, Oelkers BK, Fitts K, Whalum K, Whalum K, Hemphill AD, Manikonda J, Martinez LM, Riley EG, Roof CM, Sarwar N, Thomas DM, Ulmer E, Wallace FE, Pandey P, Roy S
- Issue date: 2020 Aug 26
- Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
- Authors: Akaji K, Konno H
- Issue date: 2020 Aug 27